In collaboration with Median Technologies, we explore a novel biomarker that is currently underutilized in oncology research that could refine patient stratification, predict treatment response, and transform cancer research and care - body composition. Read our white paper to learn why you should consider embracing this biomarker in your trials. #SyneosHealth #OncologyResearch #ClinicalTrials #Innovation #PrecisionMedicine
✨ Unlocking Body Composition’s Potential in Oncology Trials ✨ Research over the past two decades has shown that body composition is a key imaging biomarker in oncology. It can refine patient stratification, predict treatment response, and transform cancer research and care. So why is it still underutilized in oncology trials? In collaboration with Syneos Health, our latest white paper explores how to accelerate its adoption—tackling clinical evidence, accessibility, usability, and cost-effectiveness. Backed by scientific support, it makes a compelling case for implementation. ➡️ Swipe left to learn more 🔗 The full white paper is available here: https://lnkd.in/e9EiBK5X A huge thank you to the Syneos Health team— Catarina Alves Ribeiro, Senior Medical Director, and Jane Bentley, VP Clinical Strategy Lead, Oncology, and to the Median team— hubert beaumont, Lead Clinical Scientist, and Antoine IANNESSI, VP Medical Affairs—for their invaluable contributions to this work! #Oncology #ClinicalTrials #BodyComposition #CancerResearch #PersonalizedMedicine